Skip to main content
OpenTrials
Completed

NCT Number: NCT04747795

Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments

In this clinical trial the effect of early administration of Vitamin C is investigated in patients admitted at the emergency department with sepsis or septic shock.

When a patient has sepsis, his/her body is causing damage to its own tissues and organs as result of an infection. This can lead to septic shock. The patient has a low blood pressure, his/her organs stop working and the patient may even die.

The aim of this trial is to investigate the efficiency of Vitamin C in sepsis and septic shock. Vitamin C is a vitamin present in various foods and has been approved as dietary supplement by the Belgian authorities. Over the years it has been proven that Vitamin C is very safe. In addition, several studies have shown that Vitamin C can also have a protective effect. It can reduce organ damage and increase survival rates. Although several studies suggest that Vitamin C can help fight sepsis, it is not yet used in practice. This Belgian trial, in which several hospitals participate, hopes to provide a clear answer to the question: "Should Vitamin C be administered to patients admitted in an emergency department with sepsis or septic shock?"

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

GasthuisZusters Antwerpen, Antwerp, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient has a 'suspected infection': this requires the combination of antibiotic administration and body fluid cultures within the first 6 hours after Emergency Department presentation.
  • Patient has a NEWS score ≥ 5.

Exclusion criteria

  • Patient (≥18 years old) or legally authorized representative didn't provide informed consent. Delayed informed consent can be applied in cases where the patient is critically ill and no LAR is available.
  • antibiotic administration as a single dose or as a prophylactic treatment.
  • antibiotics administered without an accompanying body fluid culture according to the timeframe (within 6 hours after emergency department presentation).
  • 'Do no intubate' or 'comfort measures only' status.
  • Failure to randomize within 6 hours after Emergency Department presentation.
  • Weight < 45 kg.
  • Pregnant or breastfeeding.
  • Known allergy for Vitamin C.
  • Known history of oxalate nephropathy or hyperoxaluria.
  • Known history of glucose-6-phosphate dehydrogenase deficiency.
  • Known history of chronic iron overload due to iron storage and other diseases.
  • The patient is already on IV steroids for a reason other than septic shock.
  • Proven active COVID-19 infection (positive swab and/or CT scan positive for COVID-19 within 14 days prior to or at ED presentation).
  • Participation in an interventional trial with an investigational medicinal product (IMP) or device

Treatment and study plan

Vitamin C

Drug

IV

Other names: Ascorbic Acid

normal saline

Drug

IV

Other names: physiological serum, placebo

Primary outcomes

  1. Sequential Organ Failure Assessment (SOFA) score

    Time frame: 5 days

    Average post-baseline patient SOFA score, SOFA score range: 0-24, with 24 being the worst outcome (death)

Secondary outcomes

  1. 28-day mortality

    Time frame: 28 days

  2. Maximum SOFA score

    Time frame: 5 days

    Maximum SOFA score measured during 5 intervention period. SOFA score ranging from 0 to 24, with 24 begin the worst outcome (death)

  3. Length of hospital stay

    Time frame: 3 months

    Total length of hospital stay of the patient (including beyond intervention period)

  4. Length of ICU stay

    Time frame: 3 months

    Total length of ICU stay of the patient (including beyond intervention period)

  5. Duration Vasopressors

    Time frame: 5 days

    Total duration where vasopression is required (hours)

  6. Dosage Vasopressors

    Time frame: 5 days

    Total dosage of Vasopressors required (mcg/kg/min)

  7. need for Renal Replacement Therapy (RRT)

    Time frame: 5 days

    was RRT needed

  8. duration of Renal Replacement Therapy (RRT)

    Time frame: 5 days

    total duration of RRT (hours)

  9. Ventilator days

    Time frame: 3 months

    Total number of days the patient requires ventilator support (including beyond intervention period)

  10. Steroids

    Time frame: 5 days

    Total dose of steroids given

  11. Quality of life questionnaire (EQ-5D-5L)

    Time frame: 3 months

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

  12. Time to return to work

    Time frame: 3 months

    Time to return to work of the patient after ED admission (in days)

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Collaborators

  • Federaal Kenniscentrum voor Gezondheidszorg, Belgium

Registry information

Official study title

Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments: a Multicentre, Double Blinded, Randomized Controlled Trial: the C-EASIE Trial

Acronym: c-easie

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Feb 10, 2021
Registry last updated
Jan 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.